// App-Quantinova.ai

162 : Efficacyand safety of certolizumab pegol over four years in psoriatic arthritis patientswith and without concomitant use of DMARDs

Researchers

Presenter

  • Robert G Cooper

Principal Investigators

  • Jessica Walsh

  • Alice B Gottlieb

  • Bengt Hoepken

  • Tommi Nurminen

  • Philip J Mease

Medical Centers

  • Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK

  • Division of Hematology, The University of Utah, Salt Lake City, UT

  • Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY

  • UCB BioSciences GmbH, UCB Pharma, Monheim, GERMANY

  • UCB BioSciences GmbH, UCB Pharma, Raleigh, NC, USA

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

Locations

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT01087788

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved